HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $20.00 target price on the stock.
Separately, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.
Check Out Our Latest Report on APRE
Aprea Therapeutics Stock Up 4.6 %
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.05. The firm had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. Analysts anticipate that Aprea Therapeutics will post -2.74 earnings per share for the current fiscal year.
Insider Activity at Aprea Therapeutics
In related news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Bernd R. Seizinger bought 10,000 shares of the stock in a transaction on Friday, October 11th. The stock was acquired at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the acquisition, the director now owns 44,730 shares of the company’s stock, valued at $119,876.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Marc Duey sold 6,462 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the sale, the director now directly owns 233,651 shares in the company, valued at $1,070,121.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 42,290 shares of company stock worth $165,096. Corporate insiders own 12.80% of the company’s stock.
Institutional Investors Weigh In On Aprea Therapeutics
A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for approximately 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is currently owned by institutional investors.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
See Also
- Five stocks we like better than Aprea Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Manufacturing Stocks Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- The 3 Best Blue-Chip Stocks to Buy Now
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.